Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.37 |
| ▸ | GLRB | P48167 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21675645 | 0.84 | KDM4E (0.43) | PPARGMAPTKDM4ECFTRCYP1A2 | |
| SCHEMBL8857154 | 0.79 | PPARG (0.43) | PPARGMAPTKDM4ECFTRGAA | |
| SCHEMBL8305019 | 0.75 | RECQL (0.42) | PPARGMAPTKDM4EGAA | |
| SCHEMBL4780386 | 0.74 | KIF11 (0.34) | PPARGMAPTKDM4ECFTRMAOB | |
| SCHEMBL7822745 | 0.74 | KDM4E (0.53) | KDM4ECYP1A2CYP3A4CYP2C19LMNA | |
| SCHEMBL7998336 | 0.74 | MMP2 (0.41) | CAPN1MMP2GAACYP3A4FOLH1 | |
| SCHEMBL8405115 | 0.72 | MTNR1A (0.38) | PPARG | |
| SCHEMBL8305087 | 0.72 | PPARG (0.51) | PPARGMAPTGAALMNA | |
| SCHEMBL7812508 | 0.72 | FFAR1 (0.41) | PPARGLMNA | |
| SCHEMBL8563228 | 0.71 | PPARG (0.39) | PPARGMAPTKDM4ECYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5977374-A | 5-(4-hydroxy-OR 4-acetoxy-benzyl)-3- triphenylmethylthiazolidine-2,4-dione and method for producing same | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | claimed |
| EP-0543662-B1 | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO CO (JP) | 1996-09-18 | — | — | EP | claimed |
| JP-10338679-A | — | — | None | — | — | JP | disclosed |
| JP-9188669-A | — | — | None | — | — | JP | disclosed |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | disclosed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | disclosed |
| EP-0753298-B2 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO CO (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-20060047000-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS, INC. (US) | 2006-03-02 | — | — | US | disclosed |
| EP-1607385-A1 | Intermediates for the synthesis of benzimidazole compounds and process for the preparation thereof | Sankyo Company Limited (JP) | 2005-12-21 | — | — | EP | disclosed |
| US-6958355-B2 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20050037997-A9 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2005-02-17 | — | — | US | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
| EP-0549365-B1 | Thiazolidine compounds, their preparation and their therapeutic uses | SANKYO CO (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5436257-A | Low toxicity | SANKYO COMPANY, LIMITED (JP) | 1995-07-25 | — | — | US | disclosed |
| US-5338855-A | Treating diabetes or hyperlipemia | SANKYO COMPANY, LIMITED (JP) | 1994-08-16 | — | — | US | disclosed |
| EP-0590793-A1 | Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-04-06 | — | — | EP | disclosed |
| EP-0549366-A1 | Thiazolidine compounds containing a quinone group, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-06-30 | — | — | EP | disclosed |
| EP-0549365-A1 | Thiazolidine compounds, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-06-30 | — | — | EP | disclosed |
| EP-0543662-A2 | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047000-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | PPARG 370/4885MAPT 2743/4885KDM4E 2728/4885 |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | PPARG, PPARA, PPARD | PPARG 1/4885MAPT 4753/4885KDM4E 1152/4885 |
| US-20050037997-A9 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | PPARG 370/4885MAPT 2743/4885KDM4E 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.